Dr. Ling Yuan 袁翎
Chief Physician
Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment and research of digestive system and respiratory system tumors.
Dr. Yuan is a Chief Physician in the Department of Radiation Oncology at Henan Cancer Hospital with a medical doctorate. Dr. Yuan serves as Deputy Director of the Henan Key Open Laboratory for Esophageal Cancer and the Cancer Research Office at Zhengzhou University Medical Experimental Center. Dr. Yuan has led or participated in projects including the National 863 Major Science and Technology Special Project.
Professional roles
- Vice Chair, Esophageal Cancer Professional Committee, Henan Anti-Cancer Association
- Standing Committee Member, Research Management Professional Committee, Henan Branch of Chinese Medical Association
Name order: in Chinese the family name comes first (Yuan Ling). Papers usually list the name as Ling Yuan or Yuan L.
Selected publications
12 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Endocrinol (Lausanne), 2023 (senior author): The Nomogram predicting the overall survival of patients with pancreatic cancer treated with radiotherapy: a study based on the SEER database and a Chinese cohort. PubMed 37955009
- Front Oncol, 2023 (senior author): Choice of radiotherapy modality for the combined treatment of non-small cell lung cancer with brain metastases: whole-brain radiation therapy with simultaneous integrated boost or stereotactic radiosurgery. PubMed 37810984
- Front Oncol, 2021 (senior author): The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy. PubMed 34917497
- Pathol Oncol Res, 2021 (senior author): The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy. PubMed 34447289
- Front Oncol, 2020 (senior author): The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. PubMed 32195194
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion